Tectonic Therapeutic Inc (TECX)

$21.37 +0.37 (1.76%)
Market Cap 393.04M
Revenue (ttm) 0.00
Net Income (ttm) -57.98M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 248,900
Avg Vol 397,132
Day's Range N/A - N/A
Shares Out 18.72M
Stochastic %K 56%
Beta 3.71
Analysts Strong Sell
Price Target $79.38

Company Profile

Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein-coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin. It is also developing TX2100 for the treat...

Industry: Biotechnology
Sector: Healthcare
Phone: 339 666 3320
Address:
490 Arsenal Way, Suite 210, Watertown, United States
Matador44
Matador44 Feb. 20 at 12:16 PM
$TECX why is this -15%?
1 · Reply
BillionerOfKing
BillionerOfKing Feb. 18 at 6:00 PM
$TECX Current Stock Price: $22.43 Contracts to trade: $22.5 TECX Feb 20 2026 Call Entry: $0.40 Exit: $0.76 ROI: 90% Hold ~31 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
UgoGreg
UgoGreg Feb. 15 at 5:15 PM
$TECX https://youtu.be/nCPt9XhiRxk
0 · Reply
Linkstoc
Linkstoc Feb. 14 at 6:11 PM
$TECX Tectonic (TECX) is hiring a Director of Medical Affairs, with a base annual salary of $240,000-$360,000. Three inferences: 1. Management believes TX45 will definitely enter Phase III trials and will be approved as having a high success rate. 2. TX2100 will begin global trials, a potentially blockbuster asset. 3. The company is implementing a platform-based resource allocation strategy.
0 · Reply
Brokester
Brokester Feb. 13 at 8:55 PM
$UPB over reaction like $TECX
0 · Reply
CEOBuysDisclosures
CEOBuysDisclosures Feb. 12 at 11:20 PM
$TECX CEO purchased 2,500 shares at $21.10 for a total of $52,750. REICIN ALISE now owns 362,077 shares. https://ceo-buys.com
0 · Reply
OpenOutcrier
OpenOutcrier Feb. 12 at 12:59 PM
$TECX (+3.4% pre) Tectonic Therapeutic to Host Virtual KOL Event and Discussion of TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia, on February 24, 2026 https://ooc.bz/l/93084
0 · Reply
Dr_Jan_Itor
Dr_Jan_Itor Feb. 11 at 7:05 PM
$TECX This board is dead
1 · Reply
MarkMilla419
MarkMilla419 Feb. 11 at 4:25 PM
$TECX Tectonic Therapeutic; biotech (GPCR biologics); early-stage; partnered; platform validation needed.
0 · Reply
Linkstoc
Linkstoc Feb. 11 at 3:11 AM
$TECX Returning to TECX, only TECX can reduce the charge level (PL) from 9 to 7.8. Other companies can forget about it; they can't do it. Eli Lilly and AstraZeneca, ostensibly due to flawed experimental design leading to the misclassification of irrelevant patients, resulting in either severe illness or poor treatment outcomes, ultimately boil down to their inability to achieve precise charge expression.
0 · Reply
Latest News on TECX
Tectonic Therapeutic to Host Virtual KOL Event and Discussion of TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia, on February 24, 2026

Feb 11, 2026, 4:01 PM EST - 10 days ago

Tectonic Therapeutic to Host Virtual KOL Event and Discussion of TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia, on February 24, 2026

Tectonic: Strong Buy On Positive Phase 1b TX45 Data And 2026 Inflection Point

Nov 17, 2025, 4:22 PM EST - 3 months ago

Tectonic: Strong Buy On Positive Phase 1b TX45 Data And 2026 Inflection Point

Tectonic Therapeutic, Inc. (TECX) Discusses Positive Topline Results From Phase Ib Part B Trial of TX45 in PH-HFrEF Patients Transcript

Oct 31, 2025, 4:16 AM EDT - 4 months ago

Tectonic Therapeutic, Inc. (TECX) Discusses Positive Topline Results From Phase Ib Part B Trial of TX45 in PH-HFrEF Patients Transcript

Tectonic Therapeutic Announces Positive Topline Data from Phase 1b Part B Clinical Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFrEF

Oct 29, 2025, 4:01 PM EDT - 4 months ago

Tectonic Therapeutic Announces Positive Topline Data from Phase 1b Part B Clinical Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFrEF

Tectonic Therapeutic to Participate in September Investor Conferences

Aug 28, 2025, 9:00 AM EDT - 6 months ago

Tectonic Therapeutic to Participate in September Investor Conferences

Tectonic Therapeutic Joins Russell 3000® Index

Jun 30, 2025, 8:00 AM EDT - 8 months ago

Tectonic Therapeutic Joins Russell 3000® Index

Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF in Late-Breaking Presentation at ESC Heart Failure 2025

May 17, 2025, 10:40 AM EDT - 10 months ago

Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF in Late-Breaking Presentation at ESC Heart Failure 2025

Tectonic Therapeutic Announces First Quarter 2025 Financial Results and Recent Business Highlights

May 8, 2025, 4:01 PM EDT - 10 months ago

Tectonic Therapeutic Announces First Quarter 2025 Financial Results and Recent Business Highlights

Tectonic Therapeutic: A Buy On Massive Opportunity Of TX45 In PH HFpEF

Apr 23, 2025, 5:51 AM EDT - 10 months ago

Tectonic Therapeutic: A Buy On Massive Opportunity Of TX45 In PH HFpEF

Tectonic Therapeutic Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Mar 20, 2025, 4:01 PM EDT - 1 year ago

Tectonic Therapeutic Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Tectonic: Expansion Of TX45 Candidate Possible After Positive Interim Data

Feb 5, 2025, 11:36 AM EST - 1 year ago

Tectonic: Expansion Of TX45 Candidate Possible After Positive Interim Data

Tectonic Announces $185 Million Private Placement

Feb 3, 2025, 6:30 AM EST - 1 year ago

Tectonic Announces $185 Million Private Placement

Tectonic Therapeutic Announces Positive Interim Data from Phase 1b Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF

Jan 30, 2025, 6:30 AM EST - 1 year ago

Tectonic Therapeutic Announces Positive Interim Data from Phase 1b Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF

Tectonic Therapeutic: Protein Engineering Platform For GPCRs

Jan 5, 2025, 7:30 AM EST - 1 year ago

Tectonic Therapeutic: Protein Engineering Platform For GPCRs

Tectonic Therapeutic to Host KOL Event on the Unmet Need in Group 2 PH-HFpEF and TX45 as a Potential Treatment on Thursday, December 12, 2024

Dec 3, 2024, 4:01 PM EST - 1 year ago

Tectonic Therapeutic to Host KOL Event on the Unmet Need in Group 2 PH-HFpEF and TX45 as a Potential Treatment on Thursday, December 12, 2024

Tectonic Therapeutic To Present on December 3rd, 2024 at the Piper Sandler Healthcare Conference

Nov 26, 2024, 4:01 PM EST - 1 year ago

Tectonic Therapeutic To Present on December 3rd, 2024 at the Piper Sandler Healthcare Conference

Tectonic Therapeutic Announces Positive Phase 1a Results in AHA 2024 Presentation for TX45, a Long-acting, Fc-Relaxin Fusion Protein

Nov 11, 2024, 5:00 AM EST - 1 year ago

Tectonic Therapeutic Announces Positive Phase 1a Results in AHA 2024 Presentation for TX45, a Long-acting, Fc-Relaxin Fusion Protein

Tectonic Therapeutic to Present Phase 1a Data at AHA 2024

Oct 22, 2024, 4:01 PM EDT - 1 year ago

Tectonic Therapeutic to Present Phase 1a Data at AHA 2024

Tectonic Therapeutic: Interesting CV Disease Drug Developer

Oct 20, 2024, 6:02 AM EDT - 1 year ago

Tectonic Therapeutic: Interesting CV Disease Drug Developer

Tectonic Therapeutic Announces Favorable Phase 1a Safety, Tolerability and PK/PD Results for Lead Program TX45

Sep 19, 2024, 4:01 PM EDT - 1 year ago

Tectonic Therapeutic Announces Favorable Phase 1a Safety, Tolerability and PK/PD Results for Lead Program TX45

Tectonic Therapeutic Announces Second Quarter 2024 Financial Results and Recent Business Highlights

Aug 14, 2024, 4:01 PM EDT - 1 year ago

Tectonic Therapeutic Announces Second Quarter 2024 Financial Results and Recent Business Highlights

Tectonic Therapeutic Announces US IND Clearance for Lead Program, TX45

Jul 30, 2024, 4:01 PM EDT - 1 year ago

Tectonic Therapeutic Announces US IND Clearance for Lead Program, TX45

Matador44
Matador44 Feb. 20 at 12:16 PM
$TECX why is this -15%?
1 · Reply
BillionerOfKing
BillionerOfKing Feb. 18 at 6:00 PM
$TECX Current Stock Price: $22.43 Contracts to trade: $22.5 TECX Feb 20 2026 Call Entry: $0.40 Exit: $0.76 ROI: 90% Hold ~31 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
UgoGreg
UgoGreg Feb. 15 at 5:15 PM
$TECX https://youtu.be/nCPt9XhiRxk
0 · Reply
Linkstoc
Linkstoc Feb. 14 at 6:11 PM
$TECX Tectonic (TECX) is hiring a Director of Medical Affairs, with a base annual salary of $240,000-$360,000. Three inferences: 1. Management believes TX45 will definitely enter Phase III trials and will be approved as having a high success rate. 2. TX2100 will begin global trials, a potentially blockbuster asset. 3. The company is implementing a platform-based resource allocation strategy.
0 · Reply
Brokester
Brokester Feb. 13 at 8:55 PM
$UPB over reaction like $TECX
0 · Reply
CEOBuysDisclosures
CEOBuysDisclosures Feb. 12 at 11:20 PM
$TECX CEO purchased 2,500 shares at $21.10 for a total of $52,750. REICIN ALISE now owns 362,077 shares. https://ceo-buys.com
0 · Reply
OpenOutcrier
OpenOutcrier Feb. 12 at 12:59 PM
$TECX (+3.4% pre) Tectonic Therapeutic to Host Virtual KOL Event and Discussion of TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia, on February 24, 2026 https://ooc.bz/l/93084
0 · Reply
Dr_Jan_Itor
Dr_Jan_Itor Feb. 11 at 7:05 PM
$TECX This board is dead
1 · Reply
MarkMilla419
MarkMilla419 Feb. 11 at 4:25 PM
$TECX Tectonic Therapeutic; biotech (GPCR biologics); early-stage; partnered; platform validation needed.
0 · Reply
Linkstoc
Linkstoc Feb. 11 at 3:11 AM
$TECX Returning to TECX, only TECX can reduce the charge level (PL) from 9 to 7.8. Other companies can forget about it; they can't do it. Eli Lilly and AstraZeneca, ostensibly due to flawed experimental design leading to the misclassification of irrelevant patients, resulting in either severe illness or poor treatment outcomes, ultimately boil down to their inability to achieve precise charge expression.
0 · Reply
caprihunter
caprihunter Feb. 10 at 9:13 PM
$TECX SCORED!!!!!!!!!!!!!
0 · Reply
scorpio_nasir
scorpio_nasir Feb. 10 at 6:00 PM
$TECX some clean green candles.
0 · Reply
stocksense2
stocksense2 Feb. 10 at 5:52 PM
$TECX WTH???
0 · Reply
UgoGreg
UgoGreg Feb. 10 at 5:50 PM
$TECX https://youtu.be/otTTxAATwEY
0 · Reply
loveisnotez
loveisnotez Feb. 10 at 5:40 PM
$TECX sold too early at $20
0 · Reply
hrheasy
hrheasy Feb. 10 at 5:06 PM
$TECX reverse incoming?
1 · Reply
loveisnotez
loveisnotez Feb. 10 at 3:45 PM
$TECX $20
0 · Reply
revuelto
revuelto Feb. 10 at 2:57 PM
$TECX I appreciate the opportunity to add on the dip this morning in the 13s✌️
0 · Reply
loveisnotez
loveisnotez Feb. 10 at 2:18 PM
$TECX back to $20
0 · Reply
caprihunter
caprihunter Feb. 10 at 1:51 PM
$TECX it's totally different I don't know why small volume crashed this stock
1 · Reply
gtzmoney
gtzmoney Feb. 10 at 1:42 PM
$TECX are you buying at the bell for the rebound
0 · Reply
gtzmoney
gtzmoney Feb. 10 at 1:35 PM
$TECX why do you think the company holds all good news and polarization of bad news like they want the stock to shit the bed:::Mfers
0 · Reply